Dergiler / JAREM / 2020 / Cilt: 10 - Sayı: 2

Is Mucopolysaccharidosis a Cause of Sleep and Speech Disorders? Report of Four Cases?

Mukopolisakaridozlar Uyku ve Konuşma Bozukluklarının Bir Nedeni midir?

Dergi
JAREM
Sayfa
204–207
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Lysosomal enzyme activity examinations in leukocytes revealed increased levels of total glycosaminoglycans, heparin, and HS, and decreased HS sulphamidase activity, leading to the diagnosis of MPS III.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Mucopolysaccharidosis type III (MPS 3) is an autosomal recessive disorder caused by a deficiency of one of the four enzymes involved in the lysosomal degradation of heparan sulfate (HS).
📊
Temel Bulgular & Veri:It is often unrecognized or misdiagnosed in children as an idiopathic developmental/speech delay, attention deficit/hyperactivity disorder (ADHD), and/or autism spectrum disorder.
💡
Sonuç & Katkı:Lysosomal enzyme activity examinations in leukocytes revealed increased levels of total glycosaminoglycans, heparin, and HS, and decreased HS sulphamidase activity, leading to the diagnosis of MPS III.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Mucopolysaccharidosis type III (MPS 3) is an autosomal recessive disorder caused by a deficiency of one of the four enzymes involved in the lysosomal degradation of heparan sulfate (HS). It is often unrecognized or misdiagnosed in children as an idiopathic developmental/speech delay, attention deficit/hyperactivity disorder (ADHD), and/or autism spectrum disorder. It is characterized by progressive mental deterioration and behavioral problems with dysmorphic facial features and mild somatic signs. We report on children with ADHD who were repeatedly admitted to the pediatric psychiatry department for sleep disturbances, hyperactivity, and speech delay; and to the emergency department with accidental corrosive substance ingestion. Children with mental retardation, coarse face, and hypertrichosis were referred to the pediatric gastroenterology department for preliminary diagnosis of MPS. Lysosomal enzyme activity examinations in leukocytes revealed increased levels of total glycosaminoglycans, heparin, and HS, and decreased HS sulphamidase activity, leading to the diagnosis of MPS III.

Abstract

Mukopolisakaridoz tip III (MPS III), ya da sanfilippo sendromu, otozomal resesif kalıtılan heparan sülfat (HS) enziminin lizozomal indirgenmesinde rol alan dört enzimden birinin eksikliğine bağlıdır. Bu çocuklar yanlışlıkla idyopatik konuşma gecikmesi, dikkat eksikliği hiperaktivite sendromu (DEHS) ve/veya otizm tanısı almaktadır. Progressif mental detoriasyon, davranış problemleri, dismorfik yüz bulguları ve hafif somatik bulgularla karakterizedir. Korozif madde alımı nedeniyle acil çocuk ve çocuk gastroenteroloji bölümlerine başvuran alınan öyküde uyku bozuklukları ve geç konuşma şikayetleri bulunan ve bu nedenle de defalarca çocuk psikiyatrisine başvurdukları saptanan MPS III tanısı alan olgular sunulmuştur. Zeka geriliği, kaba yüzü ve hipertrikozu olan çocuklar, MPS ön tanısı için pediatrik gastroenteroloji bölümüne sevk edildi. Lökositlerdeki lizozomal enzim aktivitesi incelemeleri, toplam GAG, heparin ve HS seviyelerinde artış ve HS sülfamidaz aktivitesinde azalma ortaya çıkararak MPS 3 tanısına yol açtı.

🔖

Bu Makaleye Atıf Yap

URGANCI, N., KALYONCU, D., GÜMÜŞTEKİN, R. (2020). Is Mucopolysaccharidosis a Cause of Sleep and Speech Disorders? Report of Four Cases?. JAREM, Cilt: 10 - Sayı: 2, 204–207. https://ajindex.com/articles/174977

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Neufeld E., Muenzer J. The Mucopolysaccharidoses. The Online Metabolic and Molecular Bases of Inherited Disease. OMMBID McGraw- Hill Medical. 8th ed. McGraw-Hill; New York, NY, USA: 2001
  2. Poswar F.D.O, Vairo F, Burin M, Michelin-Tirelli K, Brusius-Facchin A.C, Kubaski F, Souza C.F.M.D, Baldo G, Giugliani R. Lysosomal diseases: Overview on current diagnosis and treatment. Genet. Mol. Biol. 2019;42:165–177
  3. Valstar MJ, Ruijter GJG, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 2008; 31: 240-52
  4. Wijburg FA, Węgrzyn G, Burton BK, Tylki-Szymańska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Paediatr 2013; 102: 462-70
  5. Meyer A, Kossow K, Gal A, Mühlhausen C, Ullrich K, Braulke T, et al. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics 2017; 120: 1255-61
  6. Delgadillo V, O’Callaghan Mdel M, Gort L, Coll MJ, Pineda M. Natural history of Sanfilippo syndrome in Spain. Orphanet J Rare Dis 2013; 8: 189
  7. Valstar MJ, Marchal JP, Grootenhuis M, Colland V, Wijburg FA. Cognitive development in patients with mucopolysaccharidosis type III (Sanfilippo syndrome). Orphanet J Rare Dis 2011; 6: 43
  8. Ruijter GJ, Valstar MJ, van de Kamp JM, van der Helm RM, Durand S, van Diggelen OP, et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab 2008; 93: 104-11
  9. Clarke LA, Winchester B, Giugliani R, Tylki-Szymańska A, Amartino H. Biomarkers for the mucopolysaccharidoses: Discovery and clinical utility. Mol Genet Metab 2012; 106: 395-402
  10. Buhrman D, Thakkar K, Poe M, Escolar ML. Natural history of Sanfilippo syndrome type A. J Inherit Metab Dis 2014; 37: 431-7
  11. Cross EM, Hare DJ. Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders. J Inherit Metab Dis 2013; 36: 189-200
  12. White KK. Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50(Suppl 5): 26-33
  13. Burrow TA, Hopkin RJ, Leslie ND, Tinkle BT, Grabowski GA. Enzyme reconstitution/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr 2017; 19: 628-35.